search
Back to results

Preliminary Human Trial of NPI-028

Primary Purpose

Alcoholism

Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
NPI-028
Sponsored by
National Center for Complementary and Integrative Health (NCCIH)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alcoholism

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Able to participate as an outpatient Considered of acceptable health as determined by physical examination English speaking/reading Meets DSM-IV criteria for Alcohol Dependence Have at least 10 drinking days in the past month

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    February 2, 2001
    Last Updated
    March 21, 2013
    Sponsor
    National Center for Complementary and Integrative Health (NCCIH)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00010907
    Brief Title
    Preliminary Human Trial of NPI-028
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2013
    Overall Recruitment Status
    Withdrawn
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    National Center for Complementary and Integrative Health (NCCIH)

    4. Oversight

    5. Study Description

    Brief Summary
    This research will determine whether the Chinese herbal medicine (NPI-028) can make a significant contribution to the management of withdrawal and to follow-up treatment aimed at preventing or managing relapse in both women and men alcoholics. The herbal preparation has been used historically in the treatment of alcohol intoxication and is still prescribed in China and Southeast Asia. Efficacy has been documented but awaits the application of current research methods to establish efficacy, safety, and probable mechanisms of action. Preclinical studies have been carried out in alcohol-preferring rats and vervet monkeys to test efficacy in reducing voluntary alcohol intake, measure tolerance effects, and toxicological affects. The proposed human trial will develop a placebo, establish quality control, test methods of administration, and examine compliance issues. Following these preliminary steps, a placebo controlled trial will be conducted using 160 subjects (80 subjects per treatment condition with 40 of each gender). Alcohol use, craving, health status, psychological status, and at rates will be assessed using established measures that are current in addiction research.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Alcoholism

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    NPI-028

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Able to participate as an outpatient Considered of acceptable health as determined by physical examination English speaking/reading Meets DSM-IV criteria for Alcohol Dependence Have at least 10 drinking days in the past month
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Milton L. Bullock, MD
    Organizational Affiliation
    Hennepin County Medical Center, Minneapolis
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Preliminary Human Trial of NPI-028

    We'll reach out to this number within 24 hrs